Per Alfredsson has been appointed new Chief Executive Officer of AstraZeneca AB.
Per Alfredsson took over the role after Katarina Ageborg on January 9th. He will maintain his role as Senior Vice President for Biologics Operations and will continue to lead the company’s global production network for biologics.
Katarina Ageborg will retire from AstraZeneca after almost 25 years at the company. She has been involved in the company’s development into an innovative world leading biopharmaceutical company, not least within sustainability, states AstraZeneca.
Read more: NLS’s interview with Katarina Ageborg 2019
Per Alfredsson, who has been working for AstraZeneca for over 25 years, has broad international experience of working with global production and supply chains. During the pandemic he was responsible for the establishment and startup of a supply network of more than 25 partners in over 15 countries for AstraZeneca’s vaccine – today distributed in over 3 billion doses.
“It is important that we continue the work of developing the collaboration between academia, industry and public sector in order to strengthen the life science sector’s conditions to develop long term and sustainable in Sweden,” says Per Alfredsson.
Per Alfredsson holds a Master of Science in Chemical Engineering from the Royal Institute of Technology (KTH) in Stockholm.
Photo of Per Alfredsson: AstraZeneca